AI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric Treatments
Michigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA Therapies
Table of Contents ToggleAstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equityThe obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a mergerIntellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pauseGalapagos quits cell therapy. Europe’s CGT reckoning begins.The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotechAstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equityPfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?Dermatology’s next play: bispecifics that shut down OX40L and TNFThe obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a mergerIntellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pauseGalapagos quits cell therapy. Europe’s CGT reckoning begins.The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotechNovartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrierObesity’s next arms race: staying power, not just weight lossRoche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on PetrelintidePfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a mergerThe GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity marketEU’s €12.5M Bet on Oncomatryx and Antibody-Drug Conjugates (ADCs)Marea Biotech Secures $190 Million for Heart Disease ResearchMichigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA TherapiesBreaking the Bias: How Precision Medicine Can Overcome Ancestral DisparitiesCholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B MarketSTORIES WE THINK YOU MIGHT LIKEMOST POPULARAstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equityPfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?Dermatology’s next play: bispecifics that shut down OX40L and TNFBase & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030?The hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencerThe patch that could unstick vaccination: Vaxxas’s A$90m bet on needle-free deliveryAging ScienceImpact of Space Travel on Immune Function and Potential CountermeasuresTimeline Concludes Major Immune Aging Study with Promising ResultsNew Study Highlights the Impact of Early-Life Tobacco Exposure on Accelerated AgingEpigenetic Stability Linked to Lifespan in Mammals, Research ShowDebate Highlights: Can Aging Be Halted or Reversed? Experts Weigh InAI in BiotechThe AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotechUnlocking New Frontiers: How Generative AI is Transforming Protein Design and Drug DiscoveryMichigan-Based Biotech Startup CircNova Secures $3.3M Seed Funding to Advance AI-Driven Circular RNA TherapiesHow AI is Revolutionizing Antibiotic Discovery to Combat Drug-Resistant BacteriaAstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equityBiotech StocksAlumis IPO Priced at $16, Targets $210M FundingPharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 BillionIllumina’s Market Struggles Deepen as U.S.-China Tensions EscalateGilead’s $7.8B Arcellx buy: when a partnership turns into an “option exercise” in CAR-TCRISPRIntellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pauseCRISPR-Cas9 Enhances Rice Yields Without Introducing Foreign DNACholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B MarketGene Editing for Everyone: CRISPRware and the Open-Source Biotech RevolutionBase & Prime Editing Move from Hype to Timelines: What Hits Patients 2026–2030?Food BiotechTropic Unveils Gene-Edited Non-Browning Bananas to Reduce Food WasteTexas Ban on Lab-Grown Meat Triggers Policy and Legal ShowdownsFrom Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk ProteinsFundingNovo Holdings Leads $100 Million Series C Financing for AsceneuronMarea Biotech Secures $190 Million for Heart Disease ResearchUroGen Aims to Raise $107M to Advance Innovative Obesity and Bladder Cancer TherapiesBrisbane Biotech Gelomics Raises $2.2 Million in Pre-Seed FundingGerman Biotech CatalYm Raises $150 Million for Phase 2b Cancer StudiesGenomicsFrom California to Manchester: How One Gene Therapy Is Rewriting Hunter Syndrome CareAstraZeneca Completes Equity Investment in Cellectis to Enhance Gene Therapy DevelopmentOrna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine DevelopmentEpigenetic Stability Linked to Lifespan in Mammals, Research ShowThe hypertension reset: a daily aldosterone blocker meets a twice-yearly gene-silencerInsightsFermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial StrategySyngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-UpFrom Collapse to Comeback: Inside Biotech’s ‘Death-to-Rebirth’ CycleA Champion Departs: Peter Marks’ Resignation and Biotech’s CrossroadsBeijing’s Biotech Blitz Is Outpacing America. Washington Needs a War Plan.LongevityA pill to live to 150? China’s grapeseed longevity hype gets right — and wrongManulife and World Economic Forum Launch Longevity Innovation ChallengeThe Billionaire Longevity Experiment: A Cruise Ship Promises to Extend Life—For a PriceDecoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme LongevityFrom Crypto to Cytoplasm: Brian Armstrong’s NewLimit Targets Hepatocytes for Anti-Aging BreakthroughM&A & PartnershipsRoche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on PetrelintideVector Laboratories and Absolute Biotech Announce Merger to Strengthen Life Sciences CapabilitiesOrna Therapeutics Acquires ReNAgade Therapeutics to Enhance RNA Medicine DevelopmentPharma Giant Eli Lilly to Buy Biotech Firm Morphic for $3.2 BillionMerck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 BillionNeuroscienceBreaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery€132M for a Dutch Rare-Disease Upstart: Is Europe Quietly Becoming the New Neurology Capital?NewsNovo Holdings Leads $100 Million Series C Financing for AsceneuronAI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric TreatmentsEU Sets New Goals for Advancing Biotechnology and BiomanufacturingIllumina Faces Potential $7 Billion Loss from Forced Grail Sale: An AnalysisMyricx Bio’s NMTi-ADCs Achieve Tumor Regression in Preclinical Trials AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity
Fermenting the Future: Inside the Pentagon’s $80 Million Biomanufacturing Bet—and America’s New Industrial Strategy
Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity
Breaking Barriers: BioArctic’s Blood-Brain Transport Technology and Its Impact on Neurological Drug Delivery
AI-Powered Drug Repurposing by BioXcel Therapeutics Accelerates Development of New Neuropsychiatric Treatments
